Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Justin Le Sauteur-Robitaille, Powel Crosley, Mary Hitt, Adrianne L. Jenner & Morgan Craig. (2023) Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary. Cancer Biology & Therapy 24:1.
Read now
Read now
Qiaoyun Ling, Bichun Zheng, Xudong Chen, Shaoshun Ye & Quan Cheng. (2022) The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Shyambabu Chaurasiya, Annie Yang, Seonah Kang, Jianming Lu, Sang-In Kim, Anthony K. Park, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Susanne G. Warner & Yuman Fong. (2020) Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. OncoImmunology 9:1.
Read now
Read now
Narayanasamy Badrinath, Jeong Heo & So Young Yoo. (2016) Viruses as nanomedicine for cancer. International Journal of Nanomedicine 11, pages 4835-4847.
Read now
Read now
Marcela Toro Bejarano & Jaime R Merchan. (2015) Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virotherapy 4, pages 169-181.
Read now
Read now
Eike Binz & Ulrich M Lauer. (2015) Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy. Oncolytic Virotherapy 4, pages 39-48.
Read now
Read now
Tyrel T Smith, Justin C Roth, Gregory K Friedman & G Yancey Gillespie. (2014) Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virotherapy 3, pages 21-33.
Read now
Read now
Laure Aurelian. (2013) Oncolytic virotherapy: the questions and the promise. Oncolytic Virotherapy 2, pages 19-29.
Read now
Read now
José I. Quetglas, Liza B. John, Michael H. Kershaw, Luis Álvarez-Vallina, Ignacio Melero, Phillip K. Darcy & Cristian Smerdou. (2012) Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. OncoImmunology 1:8, pages 1344-1354.
Read now
Read now
Keith A. Lawson & Don G. Morris. (2012) Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?. Expert Opinion on Biological Therapy 12:7, pages 891-903.
Read now
Read now
Christina K Lettieri, Pooja Hingorani & E Anders Kolb. (2012) Progress of oncolytic viruses in sarcomas. Expert Review of Anticancer Therapy 12:2, pages 229-242.
Read now
Read now
Articles from other publishers (59)
Karan Buntval & Hana M. Dobrovolny. (2023) Modeling of oncolytic viruses in a heterogeneous cell population to predict spread into non-cancerous cells. Computers in Biology and Medicine 165, pages 107362.
Crossref
Crossref
Wataru Matsunaga & Akinobu Gotoh. (2023) Adenovirus as a Vector and Oncolytic Virus. Current Issues in Molecular Biology 45:6, pages 4826-4840.
Crossref
Crossref
Yasmin Shakiba, Pavel O. Vorobyev, Marah Mahmoud, Azzam Hamad, Dmitriy V. Kochetkov, Gaukhar M. Yusubalieva, Vladimir P. Baklaushev, Peter M. Chumakov & Anastasia V. Lipatova. (2023) Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy. Biochemistry (Moscow) 88:6, pages 823-841.
Crossref
Crossref
Yasmin Shakiba, Pavel O. Vorobyev, Gaukhar M. Yusubalieva, Dmitry V. Kochetkov, Ksenia V. Zajtseva, Marat P. Valikhov, Vladimir A. Kalsin, Fedor G. Zabozlaev, Alevtina S. Semkina, Alexander V. Troitskiy, Vladimir P. Baklaushev, Peter M. Chumakov & Anastasia V. Lipatova. (2023) Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response. Molecular Therapy - Oncolytics 29, pages 158-168.
Crossref
Crossref
Kathryn Ottolino-Perry, David Mealiea, Clara Sellers, Sergio A. Acuna, Fernando A. Angarita, Lili Okamoto, Deborah Scollard, Mihaela Ginj, Raymond Reilly & J. Andrea McCart. (2023) Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis. Molecular Therapy - Oncolytics 29, pages 44-58.
Crossref
Crossref
M. Tommy Gambles, Jiyuan Yang & Jindřich Kopeček. (2023) Multi-targeted immunotherapeutics to treat B cell malignancies. Journal of Controlled Release 358, pages 232-258.
Crossref
Crossref
Bo Wu, Xiang Shi, Meixi Jiang & Hongxu Liu. (2023) Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer 22:1.
Crossref
Crossref
Liu Bo, Liu Tianming, Fan Fengliang, Liang Wenping, Han Jinzuo, Xue Dongbo, Ma Biao & Sun Haijun. (2023) Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis. Frontiers in Immunology 14.
Crossref
Crossref
Yanrong Zhou, Qianpeng Wang, Qi Ying, Xiaomei Zhang, Ting Ye, Kan Chen & Gongchu Li. (2023) A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells. Marine Drugs 21:2, pages 77.
Crossref
Crossref
Ghazal Asadi Garmaroudi, Farzaneh Karimi, Leila Ghanbari Naeini, Pajman Kokabian & Nozar Givtaj. (2022) Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022, pages 1-14.
Crossref
Crossref
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Eleni Karapedi, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Kostas A. Papavassiliou, Michalis V. Karamouzis & Athanasios G. Papavassiliou. (2022) Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. International Journal of Molecular Sciences 23:12, pages 6664.
Crossref
Crossref
Juliana Debrito Carten, Matthew Greseth & Paula Traktman. (2022) Structure-Function Analysis of Two Interacting Vaccinia Proteins That Are Critical for Viral Morphogenesis: L2 and A30.5. Journal of Virology 96:2.
Crossref
Crossref
Wan-Yu Chen, Yu-Li Chen, Han-Wei Lin, Chi-Fang Chang, Bing-Shen Huang, Wei-Zen Sun & Wen-Fang Cheng. (2021) Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. Cancer Letters 523, pages 149-161.
Crossref
Crossref
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault & Morgan Craig. (2021) In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. Journal for ImmunoTherapy of Cancer 9:2, pages e001387.
Crossref
Crossref
Yashbir Singh, S Deepa & Wathiq Mansoor. (2020) Functional Annotation and Identification of Putative Drug Target in VV. Functional Annotation and Identification of Putative Drug Target in VV.
Tabitha G. Cunliffe, Emily A. Bates & Alan L. Parker. (2020) Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers 12:11, pages 3327.
Crossref
Crossref
Guo-dong Cao, Xiao-bo He, Qiang Sun, Sihan Chen, Ke Wan, Xin Xu, Xudong Feng, Peng-ping Li, Bo Chen & Mao-ming Xiong. (2020) The Oncolytic Virus in Cancer Diagnosis and Treatment. Frontiers in Oncology 10.
Crossref
Crossref
Bingtao Tang, Zong Sheng Guo, David L. Bartlett, David Z. Yan, Claire P. Schane, Diana L. Thomas, Jia Liu, Grant McFadden, Joanna L. Shisler & Edward J. Roy. (2020) Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical Cancer Research 26:9, pages 2216-2230.
Crossref
Crossref
Su-Nam Jeong & So Young Yoo. (2020) Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity. Cancers 12:5, pages 1070.
Crossref
Crossref
So Young Yoo, Narayanasamy Badrinath, Hye Lim Lee, Jeong Heo & Dae-Hwan Kang. (2019) A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma. Cancers 11:11, pages 1667.
Crossref
Crossref
Tao Wu, Yulin Xiang, Tingting Liu, Xue Wang, Xiaoyuan Ren, Ting Ye & Gongchu Li. (2019) Oncolytic Vaccinia Virus Expressing Aphrocallistes vastus Lectin as a Cancer Therapeutic Agent. Marine Drugs 17:6, pages 363.
Crossref
Crossref
Ting Sun, Yanxi Luo, Minglong Wang, Tian Xie & Hui Yan. (2019) Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity. Molecular Therapy - Oncolytics 13, pages 49-57.
Crossref
Crossref
A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev & G. V. Kochneva. (2019) Targeted Therapy of Human Glioblastoma Combining the Oncolytic Properties of Parvovirus H-1 and Attenuated Strains of the Vaccinia Virus. Molecular Genetics, Microbiology and Virology 34:2, pages 140-147.
Crossref
Crossref
A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev & G. V. Kochneva. (2019) Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus. Molecular Genetics Microbiology and Virology (Russian version) 37:2, pages 83.
Crossref
Crossref
Xue Yang, Biao Huang, Lili Deng & Zhigang Hu. (2018) Progress in gene therapy using oncolytic vaccinia virus as vectors. Journal of Cancer Research and Clinical Oncology 144:12, pages 2433-2440.
Crossref
Crossref
Carmela Passaro, Sarah Di Somma, Anna Maria Malfitano & Giuseppe Portella. (2018) Oncolytic virotherapy for anaplastic and poorly differentiated thyroid cancer: a promise or a clinical reality?. International Journal of Endocrine Oncology 5:4, pages IJE10.
Crossref
Crossref
Gongchu Li, Jianhong Cheng, Shengsheng Mei, Tao Wu & Ting Ye. (2018) Tachypleus tridentatus Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. Marine Drugs 16:6, pages 200.
Crossref
Crossref
Sushil Kumar Sahu & Mukesh Kumar. 2018. Microbial Biotechnology. Microbial Biotechnology
361
382
.
Zong Sheng Guo, Zuqiang Liu, Magesh Sathaiah, Jiahu Wang, Roshni Ravindranathan, Eun Kim, Shaohua Huang, Thomas W. Kenniston, John C. Bell, Herbert J. ZehIIIIII, Lisa H. Butterfield, Andrea Gambotto & David L. Bartlett. (2017) Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Molecular Therapy - Methods & Clinical Development 7, pages 112-122.
Crossref
Crossref
So Young Yoo, Su-Nam Jeong, Dae Hwan Kang & Jeong Heo. (2017) Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma. Oncotarget 8:42, pages 71489-71499.
Crossref
Crossref
Muneyoshi Futami, Kota Sato, Kanji Miyazaki, Kenshi Suzuki, Takafumi Nakamura & Arinobu Tojo. (2017) Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma. Molecular Therapy - Oncolytics 6, pages 57-68.
Crossref
Crossref
Dana Haddad. (2017) Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. Frontiers in Oncology 7.
Crossref
Crossref
Shuchang Liu, Ludmila Ruban, Yaohe Wang, Yuhong Zhou & Darren N. Nesbeth. (2017) Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells. Heliyon 3:2, pages e00238.
Crossref
Crossref
LEE JOO WON, 박영석 & 김홍균. (2016) Oncolytic Viruses and Its Commercialization A mini review. The Korean Journal of Oral Anatomy 37:1, pages 43-54.
Crossref
Crossref
Elena P. Goncharova, Julia S. Ruzhenkova, Ivan S. Petrov, Sergey N. Shchelkunov & Marina A. Zenkova. (2016) Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. Journal of Translational Medicine 14:1.
Crossref
Crossref
K. Autio, A. Knuuttila, A. Kipar, M. Ahonen, S. Parviainen, I. Diaconu, A. Kanerva, T. Hakonen, M. Vähä-Koskela & A. Hemminki. (2016) Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies. Veterinary and Comparative Oncology 14:4, pages 395-408.
Crossref
Crossref
A.O. Sosnovtceva, N.F. Grinenko, A.V. Lipatova, P.M. Chumakov & V.P. Chekhonin. (2016) Oncolytic viruses for therapy of malignant glioma. Biomeditsinskaya Khimiya 62:4, pages 376-390.
Crossref
Crossref
Mari Hirvinen, Cristian Capasso, Kilian Guse, Mariangela Garofalo, Andrea Vitale, Marko Ahonen, Lukasz Kuryk, Markus Vähä-Koskela, Akseli Hemminki, Vittorio Fortino, Dario Greco & Vincenzo Cerullo. (2016) Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Molecular Therapy - Oncolytics 3, pages 16002.
Crossref
Crossref
Justin W. Ady, Clark Johnsen, Kelly Mojica, Jacqueline Heffner, Damon Love, Amudhan Pugalenthi, Laurence J. Belin, Nanhai G. Chen, Yong A. Yu, Aladar A. Szalay & Yuman Fong. (2015) Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma. Surgery 158:2, pages 331-338.
Crossref
Crossref
Caroline J Breitbach, Kelley Parato, James Burke, Tae-Ho Hwang, John C Bell & David H Kirn. (2015) Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Current Opinion in Virology 13, pages 49-54.
Crossref
Crossref
Suvi Parviainen, Marko Ahonen, Iulia Diaconu, Anja Kipar, Mikko Siurala, Markus Vähä-Koskela, Anna Kanerva, Vincenzo Cerullo & Akseli Hemminki. (2015) GMCSF-armed vaccinia virus induces an antitumor immune response. International Journal of Cancer 136:5, pages 1065-1072.
Crossref
Crossref
Tanja Meyer Tamguney, W. Michael Korn & Frank McCormick. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer
753
768.e3
.
Jianfang Ning & Samuel D. Rabkin. 2015. Translating Gene Therapy to the Clinic. Translating Gene Therapy to the Clinic
305
323
.
Timothy P. Cripe, Kellie B. Haworth & Peter J. Houghton. 2015. Malignant Pediatric Bone Tumors - Treatment & Management. Malignant Pediatric Bone Tumors - Treatment & Management
265
291
.
Winnie M. ChanGrant McFadden. (2014) Oncolytic Poxviruses. Annual Review of Virology 1:1, pages 191-214.
Crossref
Crossref
SeungHeui Ryu, NaHyun Kwak & DoHoon Lee. (2014) VISWES: A system for finding related vaccinia virus protein sequences in cancer immune therapy. VISWES: A system for finding related vaccinia virus protein sequences in cancer immune therapy.
Vincenzo Cerullo, Kilian Guse, Markus Vähä‐Koskela & Akseli Hemminki. 2014. Cancer Gene Therapy by Viral and Non‐viral Vectors. Cancer Gene Therapy by Viral and Non‐viral Vectors
1
20
.
G. V. Pavlova, V. P. Baklaushev, M. A. Ivanova, S. A. Goria?nov, E. Iu. Rybalkina, A. M. Kopylov, V. P. Chekhonin, A. A. Potapov & A. N. Konovalov. (2014) Modern molecular approaches to diagnosis and treatment of high-grade brain gliomas. Voprosy neirokhirurgii imeni N.N. Burdenko 78:6, pages 85.
Crossref
Crossref
Eduardo Ruiz-Hern?ndez, Michael Hess, Gustavo J. Melen, Benjamin Theek, Marina Talelli, Yang Shi, Burcin Ozbakir, Erik A. Teunissen, Manuel Ram?rez, Diana Moeckel, Fabian Kiessling, Gert Storm, Hans W. Scheeren, Wim E. Hennink, Aladar A. Szalay, Jochen Stritzker & Twan Lammers. (2014) PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. Polym. Chem. 5:5, pages 1674-1681.
Crossref
Crossref
Jahangir Ahmed, Ming Yuan, Ghassan Alusi, Nicholas R. Lemoine & Yaohe Wang. 2014. Gene Therapy of Cancer. Gene Therapy of Cancer
225
238
.
Winnie M. Chan, Masmudur M. Rahman & Grant McFadden. (2013) Oncolytic myxoma virus: The path to clinic. Vaccine 31:39, pages 4252-4258.
Crossref
Crossref
Can Xu, Haihang Li, Changqing Su & Zhaoshen Li. (2013) Viral therapy for pancreatic cancer: Tackle the bad guys with poison. Cancer Letters 333:1, pages 1-8.
Crossref
Crossref
Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Anniina Koski, Vincenzo Cerullo, Ilkka Liikanen, Siri Tähtinen, Minna Oksanen, Raita Heiskanen, Saila Pesonen, Timo Joensuu, Tuomo Alanko, Kaarina Partanen, Leena Laasonen, Kalevi Kairemo, Sari Pesonen, Lotta Kangasniemi & Akseli Hemminki. (2013) Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research 19:10, pages 2734-2744.
Crossref
Crossref
Winnie M. Chan, Eric C. Bartee, Jan S. Moreb, Ken Dower, John H. Connor & Grant McFadden. (2013) Myxoma and Vaccinia Viruses Bind Differentially to Human Leukocytes. Journal of Virology 87:8, pages 4445-4460.
Crossref
Crossref
Akinobu Gotoh, Hisao Nagaya, Takeshi Kanno, Masatoshi Tagawa & Tomoyuki Nishizaki. (2013) Fiber-substituted Conditionally Replicating Adenovirus Ad5F35 Induces Oncolysis of Human Bladder Cancer Cells in In Vitro Analysis. Urology 81:4, pages 920.e7-920.e11.
Crossref
Crossref
Vahid Salimi, Masoumeh Tavakoli Yaraki, Mahmood Mahmoodi, Shahram Shahabi, Mohammad Javad Gharagozlou, Fazel Shokri & Talat Mokhtari Azad. (2013) The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. Iranian Red Crescent Medical Journal 15:1, pages 62-7.
Crossref
Crossref
Gregory K. Friedman, Kevin A. Cassady, Elizabeth A. Beierle, James M. Markert & G. Yancey Gillespie. (2012) Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatric Research 71:2-4, pages 500-510.
Crossref
Crossref
M. H. Verheije & P. J. M. Rottier. (2012) Retargeting of Viruses to Generate Oncolytic Agents. Advances in Virology 2012, pages 1-15.
Crossref
Crossref
Guido Wollmann, Koray Ozduman & Anthony N. van den Pol. (2012) Oncolytic Virus Therapy for Glioblastoma Multiforme. The Cancer Journal 18:1, pages 69-81.
Crossref
Crossref